Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05705-z ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Naokazu Nakamura und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
- Department of Hematology and Oncology Graduate School of Medicine, Kyoto University, Kyoto, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
- Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan.
- Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Zitieren
APA
Nakamura, N., Arima, N., Takakuwa, T., Yoshioka, S., Imada, K., Fukushima, K., Hotta, M., Fuchida, S. I., Kanda, J., Uoshima, N., Shimura, Y., Tanaka, H., Ohta, K., Kosugi, S., Yagi, H., Yoshihara, S., Yamamura, R., Adachi, Y., Hanamoto, H., …, & Kansai Myeloma Forum (2024). Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05705-z
Vancouver
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, et al. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05705-z
BibTeX
@article{Nakamura2024,
author = {Nakamura, Naokazu and Arima, Nobuyoshi and Takakuwa, Teruhito and Yoshioka, Satoshi and Imada, Kazunori and Fukushima, Kentaro and Hotta, Masaaki and Fuchida, Shin-Ichi and Kanda, Junya and Uoshima, Nobuhiko and Shimura, Yuji and Tanaka, Hirokazu and Ohta, Kensuke and Kosugi, Satoru and Yagi, Hideo and Yoshihara, Satoshi and Yamamura, Ryosuke and Adachi, Yoko and Hanamoto, Hitoshi and Shibayama, Hirohiko and Hosen, Naoki and Ito, Tomoki and Shimazaki, Chihiro and Takaori-Kondo, Akifumi and Kuroda, Junya and Matsumura, Itaru and Hino, Masayuki and Kansai Myeloma Forum, Kansai Myeloma Forum},
title = {Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05705-z}
}
EUVIMED